Ultragenyx Pharmaceutical Inc.(RARE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Ultragenyx Pharmaceutical Inc. (RARE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RARE at 34.2/100 on a 32-signal composite quality model, placing it at rank #2,359 of 2,960 stocks — the bottom half of the AI-ranked universe. RARE scores in the top quartile across institutional flow (86.8), revenue growth (84.0). Areas of concern include balance sheet strength (4.2) and free cash flow (7.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Ultragenyx Pharmaceutical Inc. reports quarterly revenue of $214.0M, net income of $-92.0M, free cash flow of $-98.0M. Top institutional holders of RARE by reported 13-F value include BlackRock, RTW INVESTMENTS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. RARE trades on the Nasdaq exchange and files with the SEC under CIK 1515673. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RARE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ultragenyx Pharmaceutical Inc. directly from SEC EDGAR.